Reversal of dual epigenetic repression of non-canonical Wnt-5a normalises diabetic corneal epithelial wound healing and stem cells.


Journal

Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777

Informations de publication

Date de publication:
10 2023
Historique:
received: 10 02 2023
accepted: 18 05 2023
medline: 5 9 2023
pubmed: 18 7 2023
entrez: 17 7 2023
Statut: ppublish

Résumé

Diabetes is associated with epigenetic modifications including DNA methylation and miRNA changes. Diabetic complications in the cornea can cause persistent epithelial defects and impaired wound healing due to limbal epithelial stem cell (LESC) dysfunction. In this study, we aimed to uncover epigenetic alterations in diabetic vs non-diabetic human limbal epithelial cells (LEC) enriched in LESC and identify new diabetic markers that can be targeted for therapy to normalise corneal epithelial wound healing and stem cell expression. Human LEC were isolated, or organ-cultured corneas were obtained, from autopsy eyes from non-diabetic (59.87±20.89 years) and diabetic (71.93±9.29 years) donors. The groups were not statistically different in age. DNA was extracted from LEC for methylation analysis using Illumina Infinium 850K MethylationEPIC BeadChip and protein was extracted for Wnt phospho array analysis. Wound healing was studied using a scratch assay in LEC or 1-heptanol wounds in organ-cultured corneas. Organ-cultured corneas and LEC were transfected with WNT5A siRNA, miR-203a mimic or miR-203a inhibitor or were treated with recombinant Wnt-5a (200 ng/ml), DNA methylation inhibitor zebularine (1-20 µmol/l) or biodegradable nanobioconjugates (NBCs) based on polymalic acid scaffold containing antisense oligonucleotide (AON) to miR-203a or a control scrambled AON (15-20 µmol/l). There was significant differential DNA methylation between diabetic and non-diabetic LEC. WNT5A promoter was hypermethylated in diabetic LEC accompanied with markedly decreased Wnt-5a protein. Treatment of diabetic LEC and organ-cultured corneas with exogenous Wnt-5a accelerated wound healing by 1.4-fold (p<0.05) and 37% (p<0.05), respectively, and increased LESC and diabetic marker expression. Wnt-5a treatment in diabetic LEC increased the phosphorylation of members of the Ca We provide the first account of epigenetic changes in diabetic corneas including dual inhibition of WNT5A by DNA methylation and miRNA action. Overall, Wnt-5a is a new corneal epithelial wound healing stimulator that can be targeted to improve wound healing and stem cells in the diabetic cornea. The DNA methylation dataset is available from the public GEO repository under accession no. GSE229328 ( https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE229328 ).

Identifiants

pubmed: 37460827
doi: 10.1007/s00125-023-05960-1
pii: 10.1007/s00125-023-05960-1
pmc: PMC10474199
doi:

Substances chimiques

Wnt-5a Protein 0
MicroRNAs 0
RNA, Small Interfering 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1943-1958

Subventions

Organisme : NEI NIH HHS
ID : R01 EY013431
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY025377
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA206220
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY031377
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Raman R, Gella L, Srinivasan S, Sharma T (2016) Diabetic retinopathy: an epidemic at home and around the world. Indian J Ophthalmol 64(1):69–75. https://doi.org/10.4103/0301-4738.178150
doi: 10.4103/0301-4738.178150 pubmed: 26953027 pmcid: 4821125
Zhang Z, Yang L, Li Y et al (2023) Interference of sympathetic overactivation restores limbal stem/progenitor cells function and accelerates corneal epithelial wound healing in diabetic mice. Biomed Pharmacother 161:114523. https://doi.org/10.1016/j.biopha.2023.114523
doi: 10.1016/j.biopha.2023.114523 pubmed: 36931034
Shah R, Amador C, Tormanen K et al (2021) Systemic diseases and the cornea. Exp Eye Res 204:108455. https://doi.org/10.1016/j.exer.2021.108455
doi: 10.1016/j.exer.2021.108455 pubmed: 33485845 pmcid: 7946758
Yu FX, Lee PSY, Yang L (2022) The impact of sensory neuropathy and inflammation on epithelial wound healing in diabetic corneas. Prog Retin Eye Res 89:101039. https://doi.org/10.1016/j.preteyeres.2021.101039
doi: 10.1016/j.preteyeres.2021.101039 pubmed: 34991965 pmcid: 9250553
Vieira-Potter VJ, Karamichos D, Lee DJ (2016) Ocular complications of diabetes and therapeutic approaches. Biomed Res Int 2016:3801570. https://doi.org/10.1155/2016/3801570
doi: 10.1155/2016/3801570 pubmed: 27119078 pmcid: 4826913
Saghizadeh M, Soleymani S, Harounian A et al (2011) Alterations of epithelial stem cell marker patterns in human diabetic corneas and effects of c-met gene therapy. Mol Vis 17:2177–2190
pubmed: 21866211 pmcid: 3159681
Niehrs C (2012) The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol 13(12):767–779. https://doi.org/10.1038/nrm3470
doi: 10.1038/nrm3470 pubmed: 23151663
Clark CE, Nourse CC, Cooper HM (2012) The tangled web of non-canonical Wnt signalling in neural migration. Neurosignals 20(3):202–220. https://doi.org/10.1159/000332153
doi: 10.1159/000332153 pubmed: 22456117
Shah R, Amador C, Chun ST et al (2022) Non-canonical Wnt signaling in the eye. Prog Retin Eye Res 25:101149. https://doi.org/10.1016/j.preteyeres.2022.101149
doi: 10.1016/j.preteyeres.2022.101149
Lee JG, Heur M (2014) Interleukin-1β-induced Wnt5a enhances human corneal endothelial cell migration through regulation of Cdc42 and RhoA. Mol Cell Biol 34(18):3535–3545. https://doi.org/10.1128/MCB.01572-13
doi: 10.1128/MCB.01572-13 pubmed: 25022753 pmcid: 4135619
Chen Y, Huang K, Nakatsu MN, Xue Z, Deng SX, Fan G (2013) Identification of novel molecular markers through transcriptomic analysis in human fetal and adult corneal endothelial cells. Hum Mol Genet 22(7):1271–1279. https://doi.org/10.1093/hmg/dds527
doi: 10.1093/hmg/dds527 pubmed: 23257286
Vicente A, Byström B, Pedrosa Domellöf F (2018) Altered signaling pathways in aniridia-related keratopathy. Invest Ophthalmol Vis Sci 59(13):5531–5541. https://doi.org/10.1167/iovs.18-25175
doi: 10.1167/iovs.18-25175 pubmed: 30480741
Yuan Y, Yeh LK, Liu H et al (2013) Targeted overexpression of TGF-α in the corneal epithelium of adult transgenic mice induces changes in anterior segment morphology and activates noncanonical Wnt signaling. Invest Ophthalmol Vis Sci 54(3):1829–1837. https://doi.org/10.1167/iovs.12-11477
doi: 10.1167/iovs.12-11477 pubmed: 23412089 pmcid: 3626521
Che C, Li C, Lin J et al (2018) Wnt5a contributes to dectin-1 and LOX-1 induced host inflammatory response signature in Aspergillus fumigatus keratitis. Cell Signal 52:103–111. https://doi.org/10.1016/j.cellsig.2018.08.020
doi: 10.1016/j.cellsig.2018.08.020 pubmed: 30172652
Zhang H, Pollin TI (2018) Epigenetics variation and pathogenesis in diabetes. Curr Diab Rep 18(11):121. https://doi.org/10.1007/s11892-018-1091-4
doi: 10.1007/s11892-018-1091-4 pubmed: 30280270
Robinson R, Barathi VA, Chaurasia SS, Wong TY, Kern TS (2012) Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals. Dis Model Mech 5(4):444–456. https://doi.org/10.1242/dmm.009597
doi: 10.1242/dmm.009597 pubmed: 22730475 pmcid: 3380708
Kramerov AA, Saghizadeh M, Ljubimov AV (2016) Adenoviral gene therapy for diabetic keratopathy: effects on wound healing and stem cell marker expression in human organ-cultured corneas and limbal epithelial cells. J Vis Exp 110:e54058. https://doi.org/10.3791/54058
doi: 10.3791/54058
Gujar H, Mehta A, Li HT et al (2021) Characterizing DNA methylation signatures and their potential functional roles in Merkel cell carcinoma. Genome Med 13(1):130. https://doi.org/10.1186/s13073-021-00946-3
doi: 10.1186/s13073-021-00946-3 pubmed: 34399838 pmcid: 8365948
Kramerov AA, Shah R, Ding H et al (2021) Novel nanopolymer RNA therapeutics normalize human diabetic corneal wound healing and epithelial stem cells. Nanomedicine 32:102332. https://doi.org/10.1016/j.nano.2020.102332
doi: 10.1016/j.nano.2020.102332 pubmed: 33181273
Winkler MA, Dib C, Ljubimov AV, Saghizadeh M (2014) Targeting miR-146a to treat delayed wound healing in human diabetic organ-cultured corneas. PLoS One 9(12):e114692. https://doi.org/10.1371/journal.pone.0114692
doi: 10.1371/journal.pone.0114692 pubmed: 25490205 pmcid: 4260878
Cheng JC, Weisenberger DJ, Gonzales FA et al (2004) Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 24(3):1270–1278. https://doi.org/10.1128/MCB.24.3.1270-1278.2004
doi: 10.1128/MCB.24.3.1270-1278.2004 pubmed: 14729971 pmcid: 321446
Catalanotto C, Cogoni C, Zardo G (2016) MicroRNA in control of gene expression: an overview of nuclear functions. Int J Mol Sci 17(10):1712. https://doi.org/10.3390/ijms17101712
doi: 10.3390/ijms17101712 pubmed: 27754357 pmcid: 5085744
Lena AM, Shalom-Feuerstein R, di Val Rivetti, Cervo P et al (2008) miR-203 represses “stemness” by repressing DeltaNp63. Cell Death Differ 15(7):1187–1195. https://doi.org/10.1038/cdd.2008.69
doi: 10.1038/cdd.2008.69 pubmed: 18483491
Alkozi HA, Franco R, Pintor JJ (2017) Epigenetics in the eye: an overview of the most relevant ocular diseases. Front Genet 8:144. https://doi.org/10.3389/fgene.2017.00144
doi: 10.3389/fgene.2017.00144 pubmed: 29075285 pmcid: 5643502
Kumari N, Karmakar A, Ganesan SK (2020) Targeting epigenetic modifications as a potential therapeutic option for diabetic retinopathy. J Cell Physiol 235(3):1933–1947. https://doi.org/10.1002/jcp.29180
doi: 10.1002/jcp.29180 pubmed: 31531859
Hunter A, Spechler PA, Cwanger A et al (2012) DNA methylation is associated with altered gene expression in AMD. Invest Ophthalmol Vis Sci 53(4):2089–2105. https://doi.org/10.1167/iovs.11-8449
doi: 10.1167/iovs.11-8449 pubmed: 22410570 pmcid: 4108280
Livide G, Epistolato MC, Amenduni M et al (2012) Epigenetic and copy number variation analysis in retinoblastoma by MS-MLPA. Pathol Oncol Res 18(3):703–712. https://doi.org/10.1007/s12253-012-9498-8
doi: 10.1007/s12253-012-9498-8 pubmed: 22278416
Riau AK, Wong TT, Lan W et al (2011) Aberrant DNA methylation of matrix remodeling and cell adhesion related genes in pterygium. PLoS One 6(2):e14687. https://doi.org/10.1371/journal.pone.0014687
doi: 10.1371/journal.pone.0014687 pubmed: 21359202 pmcid: 3040179
Schmitt HM, Pelzel HR, Schlamp CL, Nickells RW (2014) Histone deacetylase 3 (HDAC3) plays an important role in retinal ganglion cell death after acute optic nerve injury. Mol Neurodegener 9:39. https://doi.org/10.1186/1750-1326-9-39
doi: 10.1186/1750-1326-9-39 pubmed: 25261965 pmcid: 4190472
Raghunath A, Perumal E (2015) Micro-RNAs and their roles in eye disorders. Ophthalmic Res 53(4):169–186. https://doi.org/10.1159/000371853
doi: 10.1159/000371853 pubmed: 25832915
Van Camp JK, Beckers S, Zegers D, Van Hul W (2014) Wnt signaling and the control of human stem cell fate. Stem Cell Rev Rep 10(2):207–229. https://doi.org/10.1007/s12015-013-9486-8
doi: 10.1007/s12015-013-9486-8 pubmed: 24323281
Liang W, Huang L, Ma X et al (2022) Pathogenic role of diabetes-induced overexpression of kallistatin in corneal wound healing deficiency through inhibition of canonical Wnt signaling. Diabetes 71(4):747–761. https://doi.org/10.2337/db21-0740
doi: 10.2337/db21-0740 pubmed: 35044447 pmcid: 8965664
Yang S, Zhang Y, Zhang Z et al (2020) Insulin promotes corneal nerve repair and wound healing in type 1 diabetic mice by enhancing Wnt/β-catenin signaling. Am J Pathol 190(11):2237–2250. https://doi.org/10.1016/j.ajpath.2020.08.006
doi: 10.1016/j.ajpath.2020.08.006 pubmed: 32858016
Yoo CB, Chuang JC, Byun HM et al (2008) Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (Phila) 1(4):233–240. https://doi.org/10.1158/1940-6207.CAPR-07-0008
doi: 10.1158/1940-6207.CAPR-07-0008 pubmed: 19138966
Sass P, Sosnowski P, Podolak-Popinigis J et al (2019) Epigenetic inhibitor zebularine activates ear pinna wound closure in the mouse. EBioMedicine 46:317–329. https://doi.org/10.1016/j.ebiom.2019.07.010
doi: 10.1016/j.ebiom.2019.07.010 pubmed: 31303499 pmcid: 6710911
Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP (2002) Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 321(4):591–599. https://doi.org/10.1016/s0022-2836(02)00676-9
doi: 10.1016/s0022-2836(02)00676-9 pubmed: 12206775 pmcid: 2713825
Beisler JA (1978) Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine. J Med Chem 21(2):204–208. https://doi.org/10.1021/jm00200a012
doi: 10.1021/jm00200a012 pubmed: 74412
Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R (2005) FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 10(3):176–82. https://doi.org/10.1634/theoncologist.10-3-176
doi: 10.1634/theoncologist.10-3-176 pubmed: 15793220
Saba HI (2007) Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag 3(5):807–817
pubmed: 18473005 pmcid: 2376088
Mann J, Mann DA (2013) Epigenetic regulation of wound healing and fibrosis. Curr Opin Rheumatol 25(1):101–107. https://doi.org/10.1097/BOR.0b013e32835b13e1
doi: 10.1097/BOR.0b013e32835b13e1 pubmed: 23114590
Nakamura K, Nakabayashi K, Htet Aung K et al (2015) DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status. PLoS One 10(3):e0120545. https://doi.org/10.1371/journal.pone.0120545
doi: 10.1371/journal.pone.0120545 pubmed: 25799509 pmcid: 4370694
Kulkarni M, Leszczynska A, Wei G et al (2017) Genome-wide analysis suggests a differential microRNA signature associated with normal and diabetic human corneal limbus. Sci Rep 7(1):3448. https://doi.org/10.1038/s41598-017-03449-7
doi: 10.1038/s41598-017-03449-7 pubmed: 28615632 pmcid: 5471258
Amador C, Shah R, Ghiam S, Kramerov AA, Ljubimov AV (2022) Gene therapy in the anterior eye segment. Curr Gene Ther 22(2):104–131. https://doi.org/10.2174/1566523221666210423084233
doi: 10.2174/1566523221666210423084233 pubmed: 33902406 pmcid: 8531184
Moulton JD (2016) Guide for morpholino users: toward therapeutics. J Drug Discov Develop Deliv 3:1023
Scoles DR, Minikel EV, Pulst SM (2019) Antisense oligonucleotides: a primer. Neurol Genet 5(2):e323. https://doi.org/10.1212/NXG.0000000000000323
doi: 10.1212/NXG.0000000000000323 pubmed: 31119194 pmcid: 6501637
Aartsma-Rus A, Krieg AM (2017) FDA approves Eteplirsen for Duchenne muscular dystrophy: the next chapter in the Eteplirsen saga. Nucleic Acid Ther 27(1):1–3. https://doi.org/10.1089/nat.2016.0657
doi: 10.1089/nat.2016.0657 pubmed: 27929755 pmcid: 5312460
Castanotto D, Rossi JJ (2009) The promises and pitfalls of RNA-interference-based therapeutics. Nature 457(7228):426–33. https://doi.org/10.1038/nature07758
doi: 10.1038/nature07758 pubmed: 19158789 pmcid: 2702667
Haque ST, Saha SK, Haque ME, Biswas N (2021) Nanotechnology-based therapeutic applications: in vitro and in vivo clinical studies for diabetic wound healing. Biomater Sci 9(23):7705–7747. https://doi.org/10.1039/d1bm01211h
doi: 10.1039/d1bm01211h pubmed: 34709244
Thiebaut C, Chesnel A, Merlin JL et al (2019) Dual epigenetic regulation of ERα36 expression in breast cancer cells. Int J Mol Sci 20(11):2637. https://doi.org/10.3390/ijms20112637
doi: 10.3390/ijms20112637 pubmed: 31146345 pmcid: 6600239
Ramsey DJ, Kwan JT, Sharma A (2022) Keeping an eye on the diabetic foot: the connection between diabetic eye disease and wound healing in the lower extremity. World J Diabetes 13(12):1035–1048. https://doi.org/10.4239/wjd.v13.i12.1035
doi: 10.4239/wjd.v13.i12.1035 pubmed: 36578874 pmcid: 9791566

Auteurs

Ruchi Shah (R)

Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Ruchi.Shah@cshs.org.
Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Ruchi.Shah@cshs.org.

Tanya M Spektor (TM)

Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Kura Oncology, Inc., Boston, MA, USA.

Daniel J Weisenberger (DJ)

Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Hui Ding (H)

Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Kunshan Xinyunda Biotech Co., Ltd., Kunshan, China.

Rameshwar Patil (R)

Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Department of Basic Science, Division of Cancer Science, Loma Linda University Cancer Center, Loma Linda, CA, USA.

Cynthia Amador (C)

Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Xue-Ying Song (XY)

Applied Genomics, Computation, and Translational Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Steven T Chun (ST)

Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
University of California Los Angeles, Los Angeles, CA, USA.

Jake Inzalaco (J)

Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
University of California Los Angeles, Los Angeles, CA, USA.

Sue Turjman (S)

Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Mount Saint Mary's University, Los Angeles, CA, USA.

Sean Ghiam (S)

Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Sackler School of Medicine, New York State/American Program of Tel Aviv University, Tel Aviv, Israel.

Jiho Jeong-Kim (J)

Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
University of California Los Angeles, Los Angeles, CA, USA.

Sasha Tolstoff (S)

Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
California Institute of Technology, Pasadena, CA, USA.

Sabina V Yampolsky (SV)

Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Duke University, Durham, NC, USA.

Onkar B Sawant (OB)

Center for Vision and Eye Banking Research, Eversight, Cleveland, OH, USA.

Yaron S Rabinowitz (YS)

Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Ezra Maguen (E)

American Eye Institute, Los Angeles, CA, USA.

Pedram Hamrah (P)

Cornea Service, New England Eye Center, Tufts Medical Center, Department of Ophthalmology, Tufts University School of Medicine, Boston, MA, USA.

Clive N Svendsen (CN)

Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Mehrnoosh Saghizadeh (M)

Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Julia Y Ljubimova (JY)

Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Terasaki Institute for Biomedical Innovation, Los Angeles, CA, USA.

Andrei A Kramerov (AA)

Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Alexander V Ljubimov (AV)

Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA. ljubimov@cshs.org.
Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. ljubimov@cshs.org.
Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA. ljubimov@cshs.org.
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. ljubimov@cshs.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH